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Abstract
Background—The Gail model has been commonly used to estimate a woman’s breast cancer
risk in a certain time period. High bone mineral density (BMD) is also a significant risk factor for
breast cancer, but it plays no role in the Gail model. The objective of this study was to investigate
whether hip BMD predicts postmenopausal breast cancer risk independently of the Gail score.
Methods—In this prospective study, postmenopausal women (N = 9,941) who had baseline hip
BMD and Gail score from the Women’s Health Initiative were included in the analysis. Their
average age was 63.0 ± 7.4 years at baseline.
Results—After an average of 8.43-years of follow-up, 327 incident breast cancer cases were
reported and adjudicated. In a multivariate Cox proportional hazards model, the hazard ratios
(95%CI) for incident breast cancer were 1.35 (1.05–1.73) for high Gail score (≥1.67%), and 1.25
(1.11–1.40) for each unit of increase in total hip BMD T-score. Restricting the analysis to women
with both BMD and Gail score above the median, a sharp increase in incident breast cancer for
women with the highest BMD and Gail scores was found (p<0.05).
Conclusions—The contribution of BMD to the prediction of incident postmenopausal breast
cancer across the entire population is independent from Gail score. However, among women with
both high BMD and high Gail score there appears to be an interaction between these two factors.
These findings suggest that BMD and Gail score may be used together to better quantify risk of
breast cancer.
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Identifying women at elevated risk is a critical step for breast cancer risk reduction.1
Recently, there has been increasing attention to developing statistical models to estimate
breast cancer risk more accurately.2 Bone mineral density (BMD) is routinely measured by
dual-energy x-ray absorptiometry (DXA) to identify women with low bone density
(osteopenia) or osteoporosis that places them at increased fracture risk requiring medical
intervention. Recently, some studies3–7 have found an association between higher BMD
and higher breast cancer risk. As a result, BMD has been proposed as a potential addition to
breast cancer risk models. However, relationships among BMD, traditional breast cancer
risk assessment tool results, such as the Gail risk model, and breast cancer incidence have
not yet been examined.
The Gail risk model is a well known tool that estimates five year and lifetime risk of
invasive breast cancer for women 35 years of age or older.8 Factors in the original Gail
model include the number of first-degree relatives with breast cancer, current age, age at
first menstrual period, number of breast biopsies, and age at first live birth.8 Since it’s
inception, the Gail score has been continually improved upon, the version of the Gail score
mostly widely used currently includes race/ethnicity, history of atypical hyperplasia and a
history of lobular carcinoma in situ.9 The Gail score has been commonly used as a clinical
and research indicator of breast cancer risk and was employed to enroll high risk women
into breast cancer prevention trials.
In this paper, we have assessed the relationships between Gail scores, baseline hip BMD and
breast cancer in a large cohort of postmenopausal women from the Women’s Health
Initiative (WHI). The primary objective of this study was to investigate whether baseline hip
BMD contributes to breast cancer risk prediction independently from Gail score. Additional
analyses were also conducted to examine the accuracy of prediction of BMD and Gail score
for incident breast cancer in postmenopausal women.
Method
Population
The study was conducted based on data from participants at three Women’s Health Initiative
BMD clinical centers where bone density scans were performed using DXA. The WHI is a
large (n = 161,809) prospective study conducted in 40 clinical centers throughout the United
States. The WHI cohort comprised non-Hispanic White, Hispanics, Black, American Indian,
and Asian/Pacific Islander postmenopausal women. There were one observational study and
four clinical trials in the WHI. Details about the WHI study design10 and exclusion and
inclusion criteria11 have been reported elsewhere.
Study procedure
At baseline, self-administered or interviewer administered questionnaires were completed by
each participant. All women had physical examinations at the time of enrollment. During the
follow-up, WHI-Observational Study (WHI-OS) women completed questionnaires annually
to update medical and other lifestyle information and WHI-Clinical Trial (WHI-CT)
participants completed the questionnaires every 6 months. The WHI study protocol was
reviewed and approved by Human Subjects Review Committees at each participating
institution and all women provided written informed consent.
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BMD was measured at three WHI BMD clinic centers (Pittsburgh, PA, Birmingham, AL,
and Tucson/Phoenix, AZ) using dual-energy x-ray absorptiometry (DXA QDR, Hologic
Inc., Waltham, MA). The positioning and analysis of DXA scans were performed according
to standard WHI protocols by radiology technicians who were trained and certified by both
the Hologic Company and the WHI Bone Density Coordinating Center at the University of
California, San Francisco. The ongoing WHI quality assurance program monitored machine
and technician performance by reviewing phantom scans, a random sample of all scans,
flagging scans with specific problems, and by controlling hardware and software changes. In
addition to daily and weekly phantom scans at each clinic, a set of calibration phantoms
were also periodically circulated and scanned across DXA instruments in the WHI. DXA-
derived BMD, body composition and T-scores were used in the analyses. Osteoporosis and
low bone density were defined by the World Health Organization (WHO) criteria based on
DXA-derived T-scores (< − 2.5 = osteoporosis, −1 to −2.5 = low bone density, > −1 =
normal) for total hip. National Health and Nutrition Examine Survey (NHANES III) was
used as the reference for hip T-score.
Variables from baseline
Questionnaires were administrated to collect information on race/ethnicity; ages at
enrollment, menarche, and first birth; number of breast biopsies; number of first-degree
relatives with breast cancer; years since menopause; menopausal hormone therapy (MHT)
use (never MHT user, past MHT user, current MHT user); dietary intakes; energy
expenditures; lifestyle factors (such as smoking etc); osteoporosis medication; osteoporosis
diagnosis; previous breast and other cancer diagnoses. Physical measurements, including
weight and height were conducted using standard protocols at the WHI clinic where the
participants were enrolled. Body mass index (BMI) was calculated as weight (kg)/height (m)
2. Gail 5-year breast cancer risk estimate was calculated with the following factors: age, age
at menarche, age at first live birth, number of breast biopsies, number of first degree
relatives with breast cancer, and race (defined as White, Black/African American, Hispanic/
Latino, or Other). History of atypical hyperplasia and history of lobular carcinoma in situ
were not collected hence were not included in the WHI calculation, although they are in the
Gail model.9
Follow-up data
Self-report of breast cancer diagnosis was first verified at each local clinical center using
medical records, then reviewed and adjudicated centrally by trained WHI physicians. Cancer
stages and receptor status of the tumor were recorded at the WHI Clinical Coordinating
Center using the Surveillance, Epidemiology and End Results Program (SEER) coding
system.12, 13
Statistical methods
Statistical analyses were done using Stata (College Station TX, version: 9.0). Women with a
cancer history at baseline were excluded from the analysis. Descriptive analyses by incident
breast cancer status were conducted. The relationships between Gail Score, osteoporosis,
and BMD were examined using ANOVA and logistic regression analysis. BMD was used
either as a continuous variable, T-score, or a categorical variable (osteoporosis, low BMD,
or normal defined by WHO).
To investigate the association between Gail score, BMD and incident invasive breast cancer,
delayed entry Cox proportional hazards models were utilized, in which age at the enrollment
was used as the entry time in the Cox models and the age at the event or loss to follow up
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was used as the exit time. It should be noted that with the delayed entry model, the incidence
of breast cancer was expressed in terms of the actual ages of the participants, not as time
under observation. We first used Gail Score and BMD each alone as the predictor in
separate univariate models. Then we included both Gail score and BMD in the Cox models
as main effects. Final models with other covariates were also developed based on forward
selection and backward elimination stepwise regressions, which yielded models with the
same covariates. The following variables were examined as potential covariates: CT versus
OS, race/ethnicity, education, and baseline BMI, weight, percent body fat, prior hormone
use, total energy intake, energy expenditure (METs), smoking status, and alcohol intake.
Schoenfeld’s residuals were used to test the proportional hazards assumption in the Cox
models and the test results showed that the proportional hazards assumption was not violated
in this sample (p=0.4653).
Receiver-operator characteristic (ROC) curve analyses were conducted to examine different
prediction properties of each Cox model. Testing for significant interactions was conducted
to explore the effect of race/ethnicity and BMI on the relationship between Gail score, BMD
and incident breast cancer. An interaction term of BMD and Gail score was also examined
in the entire sample and in a post hoc analysis with women who had both BMD and Gail
score above the median value for the respective measurement. For a more detailed analysis,
the sample was simultaneously partitioned by deciles of Gail score and BMD T-score,
yielding 100 cells. In each cell the incidence rate per 10,000 person-years was calculated,
and then these rates were smoothed and displayed as a contour plot by the Gri software
(http://gnuwin32.sourceforge.net/packages/gri.htm).
Results
Excluding 1450 women who had cancer history at baseline, the final results included 9941
women with BMD. Among them, 5516 women were enrolled in the WHI-OS and 4425
women in the WHI-CT. The average age was 63.0 ± 7.4 years (mean ± SD). The mean total
hip BMD was 0.853 ± 0.139 g/cm3 (T-score = −0.818 ± 1.054). The median 5-year Gail
score was 1.42%. After an average of 8.43-years of follow-up, 327 incident breast cancer
cases were identified.
Table 1 presents the baseline characteristics of the study participants. Breast cancer cases
were more likely to be white and more likely to have had prior biopsies. As expected, breast
cancer risk factors, including baseline hormone use, earlier menarche, family history of
breast cancer, smoking, high consumption of alcohol, higher BMD, high Gail score, high
BMI, high percent body fat, high energy intake, and low physical activity levels, were more
prevalent in the incident cases than in the no breast cancer group.
Overall, osteoporosis was more common in women with a higher Gail score (p < 0.0001)
(table 2). Hip BMD was inversely related to Gail score regardless of whether osteoporotic
categories or continuous measures of BMD (T-score) were used. However, after controlling
for age, the magnitude of this inverse relationship became much weaker (Table 3).
The age-adjusted incident rate of breast cancer was 33.1 per 10,000 person-years for women
with a low Gail score (< 1.67) and 47.8 per 10,000 person-years for women with a high Gail
score (≥1.67). The age-adjusted incident rate of breast cancer was higher in women with a
higher T-score: 45.5 per 10,000 person-years, 29.5 per 10,000 person-years, and 11.0 per
10,000 person-years respectively for women with a hip BMD T-score in the Normal, Low
BMD, and Osteoporosis range. Table 4 shows the results from Cox proportional hazards
models. Gail score and hip BMD (T-score) each was used separately as the predictor of
incident breast cancer in model 1 or model 2 respectively. Model 3 included both Gail score
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and Hip BMD (T-score). Model 4 was built on Model 3 by including additional major risk
factors for breast cancer (baseline BMI, race/ethnicity, baseline hormone use, education,
smoking and alcohol consumption) in the multivariate model. In Model 4, the association
between BMD, Gail score and incident breast cancer did not appreciably or significantly
change, suggesting the relationships between BMD, Gail Score and incident breast cancer
were not confounded by these known breast cancer risk factors.
Race/ethnicity and BMI did not significantly modify the prediction of BMD or Gail score
for incident breast cancer. Hence none of the results reported in the following tables were
stratified by these variables. Although we did not find significant interactions between the
Gail score and BMD T-score for predicting breast cancer in the entire sample, a more
detailed examination in Figure 1 suggests a slightly more complex story. For those below
the median Gail score or below the median total hip BMD T-score, the breast cancer
incidence rates are relatively flat, and do not indicate an interaction. Among those above the
median on both measures, however, there is an interaction, in which high values on both
measures are indicative of sharply increased breast cancer risk. When we restricted the
analysis to women with both Gail score and hip T-score above the median, we indeed
observed a significant interaction between Gail score and hip T-score (p= 0.002) in the Cox
proportional hazards regression.
Figure 2 is ROC analysis results for models 1–3 in table 4. The area under the curve for the
Gail model and BMD model were 0.5502 and 0.5565 respectively, which were not
significantly different from each other (P = 0.77). Including both BMD and Gail score in the
same prediction model for predicting incident breast cancer only increased the area under
the curve slightly to 0.5779, but the change from the Gail score alone model to both BMD
and Gail score model is statistically significant (p = 0.049). Including additional covariates,
the ROC area further increased to 0.62 with the 4th Model in table 4 (figure not shown).
Sensitivity analysis
When the above analyses were restricted to a subgroup with only white women or a
subgroup with just the WHI-OS participants, the results were similar to findings from the
entire sample. The number of incident breast cancers was only 35 in African Americans, and
17 in the Hispanic women, so stratified analyses were not conducted in the minority
subgroups.
Discussion
This is the first study investigating the relationship between BMD, Gail score and breast
cancer risk in a same cohort of postmenopausal women. The results from this prospective
study show that BMD and Gail score are independent predictors for incident breast cancer in
postmenopausal women. However, the relationship between Gail score and BMD with
breast cancer may not be linear and women with both high BMD and Gail score may be at
high risk for breast cancer. The observed inverse relationship between BMD and Gail score
can be largely explained by age. This may be due to the fact that both osteoporosis (low
bone density) and breast cancer (higher Gail score) risks increase in older women.
Since its first publication in 1989, the Gail model has by far been the most popular algorithm
in breast cancer prediction in the United States and has contributed to breast cancer research
and clinical management in a significant way. Considering other risk factors and ethnic
variations, the Gail model has been tested and modified in many previous studies throughout
the years.9, 14, 15 It is a general consensus that the prediction accuracy of the original Gail
model is moderate at the population level. Based on the area under the curve, the prediction
accuracy was low (ROC area = 0.55) in this current study. Most published studies reported
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ROC area of 0.6 or larger.14, 16, 17 One explanation of this lower prediction accuracy in
the current study may be related to both the relatively small number of breast cancer cases
and the diverse multiethnic cohort in this study. Indeed, after controlling for some selected
characteristics of the women, such as BMI and race/ethnicity, the ROC area was improved
to 0.62 in this study. The best published ROC area is only 0.6817, much less than the
prediction models for other health outcomes, such as cardiovascular disease18 and
osteoporosis.19
Results from this study confirm and extend the findings in a number of previously published
large prospective studies, suggesting that postmenopausal women with high bone mass or
bone mineral density were more likely to develop breast cancer in comparison to women
with low BMD. 3, 6, 20, 21 More interestingly, we found that this relationship is
independent from Gail score.. Previously the Study of Osteoporotic Fractures3 reported that
among postmenopausal women in the U.S., those with BMD above the 25th percentile had a
2–2.5 fold increased risk of developing breast cancer compared with women with BMD
below the 25th percentile. The underlying factors linking BMD with breast cancer may
include body size and life-long estrogen exposures, as adjusting for current circulating
estrogen level and BMI, the relationship between BMD and breast cancer disappeared.21
However, another study found that adjusting for BMI and lifetime ovulation did not
completely explain the association between BMD and breast cancer risk.4 In our study,
adjusting for BMI, baseline hormone use and a number of other variables did not
significantly alter the relationship between BMD and breast cancer risk either. It must be
pointed out that we did not have direct measurements on endogenous estrogen in our study,
so residual confounding may exist in the analysis. In addition, the difference in the findings
from previous studies may be due to the fact that the relationship between BMD and current
circulating estrogen level is stronger than the relationship between BMD and lifetime
ovulation (or baseline hormone use). Hence, adjusting for the later factors could not
disassociate the connection between BMD and breast cancer risk.
Our results suggest that when BMD is available it is an attractive alternative measure in
assessing breast cancer risk. Since BMD was similar to the Gail model in predicting breast
cancer risk in our study, this information could be of additional use to women receiving
DXA scanning for osteoporosis diagnosis, particularly if this finding can be confirmed by
other cohort studies. Clinicians and researchers would then be able to identify a group of
women at high risk for breast cancer using multiple approaches, such as Gail score, BMD or
breast density as suggested by another investigation.17 Our results and Tice’s study17 both
indicated that even when Gail score is available, adding other variables, such as BMD or
breast density may still significantly improve the prediction of the models.
The interrelationships between Gail score, BMD and breast cancer risk were not
significantly confounded by BMI, race/ethnicity, baseline hormone use, or physical activity.
However, considering these factors may enhance the prediction. Whether the prediction for
breast cancer can be significantly improved by including breast density measures in the
BMD and Gail combined model is an interesting question for future research.
We did not observe any significant effect modification by race/ethnicity, or BMI on the
relationship between BMD, Gail score and incident breast cancer. However, due to the small
number of breast cancer cases in the minority groups, these questions should be tested in
other studies with larger number of minority breast cancer cases. The other limitations of
this study include healthy volunteer phenomena. WHI study is not a population-based study
and the women who are willing to participate in a long cohort study may be healthier than
the general population. Therefore whether our finding is generilizable to other populations
will need to be found out in future studies. Since this study used information from the WHI,
Chen et al. Page 6













the data collection is restricted by the WHI study design. So, there may be residual
confounding from either unmeasured variables (such as genetic factors and life time
estrogen exposure) or measurement errors in the covariates (such as baseline hormone use)
that were included in the models.
Women with both very high Gail score and BMD are at exceptional high risk for breast
cancer in this study. However, the interaction between the Gail score and BMD T-score is
confined to the higher risk groups on both measures. Since the number of women in the
doubly-higher risk category is relatively small, the statistical interaction analysis in the
entire sample may be mainly driven by the women with low to average Gail score or BMD,
and so significant interactions of BMD and Gail score were not detected there. Only a large
cohort, such as WHI, allows investigating these associations in the extreme group of
women, and this intriguing finding would be missed in smaller studies. Cautions should be
given to intemperate this finding since it was derived from a post hoc analysis and needs to
be confirmed by other studies.
There are number of major strengths in this study, such as the prospective study design and
adjudicated incident breast cancer cases. In addition, this study also benefits from the
comprehensive measurements of BMD using a state-of -the-art technique and the
availability of measurements on many risk factors for breast cancer. However, due to the
large number of incident cases from white women, the study results are likely driven by
white women and this is a limitation of this study. Whether there is any effect modification
of race/ethnicity on the relationship between Gail score, BMD and breast cancer needs
further investigation.
In conclusion, the association between BMD and incident breast cancer is independent from
Gail score. Hip BMD and Gail score were similar in predicting incident breast cancer. Using
both BMD and Gail score together may improve the performance of the prediction model on
incident breast cancer in postmenopausal women, but the gain in accuracy of the prediction
is small. The prediction model seems most applicable to the women with both extremely
high Gail score and BMD. Future studies should investigate whether incorporating BMD
and Gail score with other risk factors, such as breast density, can further improving the
identification of women at high risk for developing breast cancer.
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Contour Plot of Breast Cancer Incidence (per 10,000 Person Years) by Decile of Hip T
Score and Gail Score
• Hip T –score decile = −2.19, −1.75, −1.43, −1.15, −0.87, −0.59, −0.28, 0.08, 0.57
(10th -90th percentiles, by 10, respectively)
• Gail score (%) decile = 0.75, 0.96, 1.13, 1.27, 1.42, 1.56, 1.78, 2.01, 2.68 (10th
-90th percentiles, by 10, respectively)
• The numbers in the boxes (such as 30, 40…110) are the numbers of incidence
breast cancer per 10,000 person-years.
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ROC for Predicting Incident Breast Cancer by Gail Score (Model 1), BMD (Model 2) and
both Gail Score and BMD (Model 3)
 Gail score > 1.67 0.5502
 Hip T Score 0.5565
 Gail + Hip T Score 0.5779
 Reference
Model ROC SE P value*
Model 1 – Gail (≥ 1.67%) 0.5502 0.0140
Model 2 – Hip T score 0.5565 0.0159 0.7721
Model 3 – Gail + Hip T score 0.5779 0.0166 0.0490
* 
p value testing the difference from the Gail score alone model
N = 9936
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Table 1
Baseline Characteristics of the Participants
Categorical Variables
No Incident Breast Cancer (N = 9614) Incident Breast Cancer (N = 327)
n (%) n (%) P value
Age
 50–59 3404 (35.4) 102 (31.2)
 60–69 4140 (43.1) 139 (42.5)
 70–79 2070 (21.5) 86 (26.3) 0.085
Ethnicity
 White (non Hispanic) 7388 (76.9) 270 (82.6)
 Black or African American 1397 (14.6) 35 (10.7)
 Hispanic/Latino 628 (6.5) 17 (5.2)
 American Indian/Alaskan Native 114 (1.2) 3 (0.9)
 Other 76 (0.8) 2 (0.6) 0.219
Baseline HRT Use
 Never Used 4547 (47.3) 167 (51.2)
 Past User 1550 (16.1) 39 (12.0)
 Current User 3513 (36.6) 120 (36.8) 0.108
Age at First Birth (GM)
 Less than 19 1603 (16.7) 57 (17.4)
 20–24 3739 (38.9) 109 (33.3)
 25–29 or nulliparious 2823 (29.4) 114 (34.9)
 30 or older 589 (6.1) 21 (6.4)
 Unknown 860 (9.0) 26 (8.0) 0.180
Number of Biopsies (GM)
 None 6469 (67.3) 196 (59.9)
 1 1229 (12.8) 73 (22.3)
 2 or more 550 (5.7) 20 (6.1)
 Unknown 1366 (14.2) 38 (11.6) < 0.001
Age at Menarche
 14 Years or Older 2413 (25.1) 76 (23.2)
 12–13 Years 5200 (54.1) 177 (54.1)
 11 Years or Younger 1959 (20.4) 72 (22.0)
 Unknown 42 (0.4) 2 (0.6) 0.784
First Degree Relatives w/Breast Cancer
 0 7878 (82.0) 240 (73.6)
 1 1100 (11.5) 53 (16.3)
 2 or more 117 (1.2) 12 (3.7)
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Categorical Variables
No Incident Breast Cancer (N = 9614) Incident Breast Cancer (N = 327)
n (%) n (%) P value
 Unknown 511 (5.3) 21 (6.4) < 0.0001
Smoking
 Never Smoked 5204 (54.9) 154 (47.5)
 Past Smoker 3513 (37.1) 141 (43.5)
 Current Smoker 763 (8.1) 29 (9.0) 0.031
Alcohol Consumption
 Non drinker 1577 (16.6) 50 (15.4)
 Past drinker 2122 (22.3) 54 (16.7)
 <1 drink per month 1254 (13.2) 44 (13.6)
 <1 drink per week 1874 (19.7) 60 (20.4)
 1 to <7 drinks per week 1957 (20.5) 70 (21.6)
 7+ drinks per week 745 (7.8) 40 (12.4) 0.023
Osteoporosis (measured at Hip)
 Normal 5323 (55.4) 210 (64.2)
 Low bone density 3813 (39.7) 107 (32.7)
 Osteoporosis 478 (5.0) 10 (3.1) 0.005
High Risk Gail Score
 < 1.67% 6258 (65.1) 180 (55.1)
 ≥ 1.67% 3356 (34.9) 147 (45.0) < 0.0001
Continuous Variables
No Incident Breast Cancer mean (95% CI) Incident Breast Cancer mean (95% CI) P value
BMI (kg/m2) 28.2 (28.1, 28.3) 29.0 (29.4, 29.7 0.014
% Fat 43.8 (43.7, 44.0) 44.3(43.5, 45.1 0.270
Total Energy Intake (kcal) 1661.5 (1645.2, 1677.9) 1676.4(1598.3, 1754.4) 0.747
METs per week 11.4 (11.1, 11.7) 11.3(9.9 12.7) 0.905
Years Since Menopause 16.1 (15.9, 16.3) 15.7 (14.6 16.8) 0.527













Chen et al. Page 14
Table 2
Percent of Women at High Risk of Breast Cancer by Osteoporosis
Categories Osteoporosis Categories based on Hip T score*
Gail Score
TotalLow Gail Score (< 1.67%) High Gail Score (≥1.67%)
n = 6,438 n = 3,503 n = 9941
N (%) N (%) N (%)
Normal 3,862 (60.0) 1,671 (47.6) 5,533 (55.7)
Low BMD 2,328 (36.1) 1,592 (45.5) 3,920 (39.4)
Osteoporosis 248 (3.9) 240 (6.9) 488 (4.9)
*
P <0.001 in Chi square test for difference in osteoporosis categories by Gail score group
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Table 3
Association between Hip T-score and Gail Score*
Crude Age-Adjusted
OR 95% CI OR 95% CI
Model 1 – Osteoporosis Category**
 Normal Reference -- Reference --
 Low bone density 1.59 1.45, 1.72 1.09 1.00, 1.20
 Osteoporosis 2.22 1.85, 2.68 1.05 0.86, 1.29
Model 2 – Continuous Variable
 T-score 0.76 0.73, 0.79 0.96 0.92, 1.01
*
Results from logistic regression predicting high risk Gail score (≥ 1.67%)
**
T-score < − 2.5 = osteoporosis, −1 to −2.5 = low bone density, > −1 = normal
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Table 4
Cox Proportional Hazards Models for Incident Breast Cancer
HR 95% CI P- values
Model 1: Gail Score
 Gail score (≥1.67%) 1.44 1.14, 1.83 0.002
Model 2: Hip T-score
 Hip T – score 1.26 1.13, 1.39 < 0.001
Model 3: Gail & Hip T-score
 Gail score (≥1.67%) 1.47 1.17, 1.86 0.001
 Hip T-score 1.26 1.14, 1.40 < 0.001
Model 4: Gail, Hip T-score & Covariates*
 Gail score (≥1.67%) 1.35 1.05, 1.73 0.02
 Hip T-score 1.25 1.11, 1.40 < 0.001
*
Adjusted for Ethnicity, BMI, Baseline Hormone Use, Education, Smoking, and Alcohol Consumption in the multivariate model.
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